^
Association details:
| Biomarker: | EGFR expression |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | Koselugo (selumetinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Proteomics identifies EGF-like domain multiple 7 as a potential therapeutic target for epidermal growth factor receptor-positive glioma
Published date:
09/04/2020
Excerpt:
Selumetinib treatment showed tumor reduction effect in EGFR-positive glioblastoma xenograft mouse model.
DOI:
10.1002/cac2.12092
